Figure 3.

Specific ablation of EpCAM results in increased SKBR3 breast cancer cell viability. (A) EpCAM-shRNA specifically ablates EpCAM protein levels in MCF-10A, MDA-MB-231, and SKBR3 cells 72 h post infection relative to shGFP control vector. (B) Crystal violet-stained plates depicting cell growth differences in MCF10A, MDA-MB-231, and SKBR3 cells 14 days post infection. Plates representative of three independent experiments. (C) Crystal violet growth assay used to quantify the growth differences between the breast cancer cell lines. A full color version of this figure is available at the British Journal of Cancer online.